[Clinical survey on cardiotoxicity of tegafur (FT-207)--compilation of a nationwide survey].
To examine FT-207 cardiotoxicity, medical records of 223 cancer patients from 23 institutions throughout Japan were subjected to analysis. ECG changes occurred in 11/108 patients and 4/115 patients after iv and po administration of FT-207 respectively. ST . T wave changes resembling to coronary T wave occurred in 4 patients without subjective or objective symptoms of cardiac disturbance after surgery followed by iv injection for a given period. These 4 patients did not show symptoms such as chest pain and tachycardia accompanying with ECG changes described in foreign literatures concerning 5-FU, and it was not clear whether these ECG changes reflected cardiac disturbance or not. On the other hand, other ECG changes consisted of non-specific changes in ST . T wave, and they were considered to be of no significance in clinical evaluation because of influence of background factors such as surgery and adjunct chemotherapy. Although this surveillance did not provide a given relationship between FT-207 and cardiac disturbance, it is recommended that especially iv injection should be taken with ECG monitoring.
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D004562:Electrocardiography; D005260:Female; D005472:Fluorouracil / Q000031:analogs & derivatives*; D006321:Heart / Q000187:drug effects*; D006801:Humans; D007263:Infusions, Parenteral; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy; D005641:Tegafur / Q000008:administration & dosage / Q000009:adverse effects*
D005641:Tegafur; D005472:Fluorouracil